Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cyberattacked Dr. Reddy’s Keeps Eye On Sputnik Plans

'Controlled And Cautious' Recovery

Executive Summary

Dr Reddy’s management clears air on ransomware attack and says all critical operations are being enabled in a 'controlled and cautious' manner. The Indian firm also shared a timeline for its partnered Russian COVID-19 vaccine amid a free supply chorus in India.

You may also be interested in...



Expert View: Second, Third Wave COVID-19 Vaccines Still Have Much To Vie For

In a broad-ranging interview with Scrip, the ex-CEO of India's Hilleman Laboratories compares the profiles of leading COVID-19 vaccines and urges caution around how far some of the new data now rolling out should be interpreted. The executive also outlines solutions to tackle logistics issues and "vaccine hesitancy" in countries like India.

Experts Skeptical As Russia’s COVID-19 Vaccine Outshines Pfizer Results

Russian claims of superior efficacy two days after Pfizer’s good news look politically motivated

Perrigo’s Loss Is Lupin’s Gain On Albuterol

Having gained from Perrigo’s US withdrawal of generic ProAir (albuterol sulphate), Lupin plans to ramp up capacity by its financial fourth quarter as demand is seen rising on account of flu and COVID-19 cases in the US. Meanwhile, FDA observations at its Somerset facility provide a dampener.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel